Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RML-TB
2023-509075-17-00Phase 2Completed
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Jul 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifampicin, moxifloxacin and linezolid in pulmonary tuberculosis (TB) (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoints: Proportion of patients with sterilization of sputum culture in liquid medium at 8 weeks and Proportion of patients with grade 3 or higher adverse events. Started Jul 2022; status: completed.
02
Drugs
rifampicinmoxifloxacinlinezolid
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on 2023-509075-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509075-17-00.